Virpax Receives pre-IND Application Guidance From The FDA For Its CBD-Based Drug Candidate For Epilepsy

Virpax Pharmaceuticals, Inc. VRPX, a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral barrier indications, has received pre-investigational new drug application guidance from the U.S. Food and Drug Administration for NobrXiol, the company’s product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults.

NobrXiol utilizes the Nanomerics molecular envelope technology as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve.

The main purpose of a pre-IND submission is to obtain FDA guidance on the overall development plan for a new drug and to identify any need for further data prior to submitting the IND.

“Virpax now has guidance on how to proceed with the IND enabling studies and possible regulatory pathways to pursue for NobrXiol,” stated Dr. Sheila A. Mathias, chief scientific officer for Virpax. “Based on the written responses from the FDA and its recommendations, we believe that we can proceed with the next steps in the process towards an IND application for this product candidate.”

Anthony P. Mack, chairman and CEO of Virpax, stated: “This is a significant step forward for the NobrXiol project and we are very pleased with the outcome of the pre-IND meeting with the FDA. We believe this product candidate has potential benefits over existing oral CBD treatments for epilepsy including Dravet syndrome and Lennox-Gastaut syndrome. We believe that by using the molecular envelope technology delivery system there may be significant advantages for patients including fewer side effects, avoidance of drug-to-drug interaction and lower dosing of CBD required,” concluded Mack.

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo by Jeff W on Unsplash